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Abstract C3 is the central component of the complement
system and activation of C3 via any of the three major
activation pathways—the classical, the lectin and the alter-
native pathways—results in initiation of the terminal com-
plement pathway and release of the anaphylatoxin C3a.
Both terminal pathway activation and signalling of C3a
and its inactivation product C3a-desarg via the C3a receptor
and C5a-like receptor 2, respectively, can induce inflamma-
tory, immunomodulatory and metabolic responses. C3 has
been implicated in metabolic disorders, notably adiposity,
dyslipidaemia, insulin resistance, liver dysfunction and dia-
betes, and C3 is increasingly recognised as a cardiometa-
bolic risk factor. C3 may play a role in the macrovascular, as
well as microvascular, complications of diabetes. Moreover,
C3 may interact with the coagulation system and as such
also contribute to a procoagulant, hypofibrinolytic and, ulti-
mately, prothrombotic state. Recent data suggest a diabetes-
dependent incorporation of C3 into fibrin clots, with con-
comitant effects on clot characteristics. Taken together, ep-
idemiological and experimental evidence concordantly
point to a role of complement C3 in metabolic, atheroscle-
rotic/atherothrombotic and microangiopathic processes and
further research should be directed towards the elucidation
of complement function and activation in cardiometabolic
disorders.
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Abbreviations
ASP Acylation-stimulating protein
C3aR C3a receptor
C5L2 C5a-like receptor 2
CVD Cardiovascular disease
MAC Membrane-attack complex
NAFLD Non-alcoholic fatty liver disease
TCC Terminal complement complex
The complement system, a complex protein network initial-
ly identified as part of the innate immune system, is increas-
ingly recognised as an essential regulator of cell and tissue
homeostasis. It consists of soluble and membrane-bound
proteins functioning in cascades of stepwise protease acti-
vation; effector functions include the release of anaphyla-
toxins and formation of terminal complement complexes
(TCCs). Anaphylatoxins operate by binding to their recep-
tors on a variety of immune and non-immune cells, where
they exert proinflammatory, immunomodulatory and meta-
bolic effects. TCCs are assembled upon membranes, where
they exert stimulatory effects on cell cycle and cell metab-
olism (sublytic TCCs) or promote cytolysis when present in
higher amounts (lytic TCCs, also referred to as membrane-
attack complexes [MACs]).
C3 lies at the heart of the complement network, as all
three major activation pathways may result in cleavage of
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DOI 10.1007/s00125-012-2462-zC3 and initiation of the downstream terminal pathway. Sys-
temic levels of C3 may reflect the potential for complement
activation. Upon activation of C3, C3a and C3b are gener-
ated. Once formed, the anaphylatoxin C3a is rapidly desar-
ginated by a carboxypeptidase, generating C3a-desarg.
Although this was previously thought to be an inactivation
process, C3a-desarg has been recognised as a lipogenic
hormone and is now also known as acylation-stimulating
protein (ASP) [1]. C3b is instrumental in the activation of
the terminal pathway of complement activation, which leads
to formation of TCCs/MACs (Fig. 1).
Recent data suggest that C3 plays a role in metabolic
disorders. For example, a high systemic concentration of C3
was shown to be independently associated with the inci-
dence of type 2 diabetes, at least in men [2]. Additionally,
systemic C3 levels have been associated with several diabe-
tes risk factors, including adiposity (waist, BMI), serum
triacylglycerol and insulin resistance (as reviewed in [3]).
Plasma C3 levels are also higher in non-alcoholic fatty liver
disease (NAFLD) [4], a common comorbidity associated
with obesity and in type 2 diabetes, and possibly also in
type 1 diabetes; in agreement with this observation, alanine
aminotransferase—a marker of liver dysfunction—was also
associated with plasma levels of C3 [5]. The link between
systemic C3 and adiposity is substantiated by the observa-
tions that adipose tissue secretes C3, that weight gain is
associated with an increase in C3 and that C3 decreases
upon weight loss [3]. Further evidence supporting a poten-
tial role for C3 in (the development of) diabetes and associ-
ated metabolic disorders is the strong association of C3,
which is an acute phase reactant, with inflammatory markers
[6]. In addition, complement activation can promote system-
ic inflammation [7].
At least two signalling pathways have been identified that
may contribute to the association of C3 activation with
insulin resistance, adipose tissue function and lipid metabo-
lism. First, expression of the C3a receptor (C3aR) is partic-
ularly high in white adipose tissue and is strongly
upregulated after a high-fat diet [8]. Interruption of the C3–
C3a–C3aR axis in a C3aR
−/− mouse model prevented diet-
induced insulin resistance [8]. Second, interruptionof the C3–
(C3a)–C3a-desarg/ASP–C5a-like receptor 2 (C5L2) pathway
in a C5L2
–/– mouse model had multiple metabolic effects,
including reduced triacylglycerol synthesis in adipose tissue
and delayed triacylglycerol and glucose clearance [9]. Re-
duced signalling of ASP via C5L2 (ASP resistance) may
contribute to altered adipose tissue metabolism in obesity/
insulin resistance phenotypes in humans [10]. Overall, sub-
stantial evidence points towards an active role of C3, at least
partly via C3 activation, in diabetes-related metabolic dis-
eases. However, the causal relationships and order of the
events that occur in the vicious cycles of adiposity, insulin
resistance and inflammation, remain to be unravelled.
C3 may also play a role in the cardiovascular complica-
tions of diabetes and related metabolic diseases. C3 has
repeatedly been shown to be associated with different man-
ifestations of prevalent and incident cardiovascular disease
(CVD), often—but not always—independently of classical
risk factors [3]. The observation that the associations with
CVD risk factors and disease manifestations are not uniform
suggests that there may be distinct properties of C3 contrib-
uting to the development of CVD. Mechanistically, the
involvement of C3 in the atherosclerotic process is illustrat-
ed by the presence of C3 and its activation products in
atherosclerotic plaques. A causal role was deduced from
animal studies showing that deposition of lipids and
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Fig. 1 Adiposity, inflammation, immune activation, insulin resistance,
hypertriglyceridaemia and, potentially, hyperglycaemia may lead to
increased systemic levels of C3. C3a and C3b are generated upon
activation of C3. C3b is part of the multi-step complement activation
cascade that eventually leads to the formation of soluble (s) TCCs/
MACs. The anaphylatoxin C3a is rapidly degraded into its
desarginated form, which is also known as ASP. Both C3a and C3a-
desarg/ASP can, via binding to their respective receptors (C3aR and
C5L2), exert relevant effects with respect to diabetes and CVD. The
solid arrows denote direct effects, the dotted arrows denote more distal
effects and the lightening bolts indicate activation
882 Diabetologia (2012) 55:881–884complement in the intima precedes the infiltration of inflam-
matory cells and foam cell development [11].
The role of complement activation in diabetic vascular
complications may not be confined to macrovascular disease.
The complement system may also contribute to compromised
microvascular function, and activation of complement, includ-
ing C3, may thus contribute to the diabetic nephropathy, reti-
nopathy and neuropathy. Its role in nephropathy is supported
by the presence of activated C3 in glomeruli and glomerular
capillaries of animal models of type 1 and type 2 diabetes [12,
13].Furthermore,C3activationmayaggravateexistingkidney
disease since non-selective filtration of complement proteins
may result in intratubular complement activation and tubular
damage [14, 15]. Support for a role of C3 in retinopathy and
neuropathyisprovidedbydataindicatingthatactivatedC3and
TCC/MAC (representing terminal pathway activation) are
present in the retinal vessels [16] and choriocapillaries [17]
of patients with diabetic retinopathy and in the walls of endo-
neurial microvessels of patients with diabetic neuropathy [18].
Activation of the complement system may contribute to
diabetic vasculopathy via interactions with the coagulation
system. Based on the early observation that the complement
system is activated during blood clotting, multiple interac-
tions between the complement and the coagulation/fibrino-
lysis cascades have been revealed (as reviewed in [19]).
Several enzymes of the coagulation/fibrinolysis cascade
can activate C3 and, conversely, several components of the
complement system appear to be involved in the activation
of thrombin and the modulation of platelet aggregation.
These observations position the complement system as part
of a complex protease network that is characterised by
substantial crosstalk between complement and the coagula-
tion/fibrinolysis system. This considerable interplay might
represent another cluster of proteins in which complement
participates in macro- and microvascular disease risk by
conferring procoagulant, hypofibrinolytic and ultimately
prothrombotic properties.
In this issue of Diabetologia, Hess and colleagues present
novel aspects of the role of C3 in diabetes with regard to
CVD risk [20]. They propose a mechanism in which C3
participates in a hypofibrinolytic, and thus prothrombotic,
state. It had previously been recognised that C3 is incorpo-
rated into fibrin clots, and that this is accompanied by a
modified fibre architecture, rendering clots more resistant to
lysis [21, 22]. Hess et al [20] expand on these previous
findings by showing that clots from type 1 diabetic patients
are more resistant to fibrinolysis, which appears to be due to
altered clotting and lysis features of diabetic fibrinogen and
C3. In a variety of experiments they demonstrate that clots
generated from diabetic fibrinogen incorporate more C3,
resulting in more consolidated clots. On the other hand,
exposure of both diabetic and control fibrinogen to diabetic
C3 produces clots more resistant to lysis. Furthermore, in
diabetic individuals, clot lysis time was correlated with
plasma C3 levels. The authors concluded that the effect of
C3 on clot properties is more pronounced in diabetes. It was
also suggested that systemic C3 levels and C3-mediated
fibrin clot formation and lysis properties may be influenced
via glycaemic control, although these were essentially un-
controlled observations that clearly need corroborating.
The mechanism of diabetes-dependent C3 incorporation
into fibrin clots with concomitant effects on clot character-
istics adds to our knowledge of the broad aspects of com-
plement functioning in type 1 and, potentially also, type 2
diabetes, and may in due course be extended to related
disorders, including obesity and NAFLD. Unfortunately,
Hess et al [20] did not consider C3 activation in their
experiments, which hampers full comprehension of the pre-
sented data. For a better understanding of the C3 coagula-
tion/fibrinolysis interaction, it is essential to know to what
extent C3 activation is involved. If the mechanism presented
by Hess et al takes place basically without C3 activation,
this would represent a completely novel, direct mode of C3
operating on CVD risk, whereby C3 would contribute to a
hypofibrinolytic/prothrombotic state solely by its presence
in clots, thereby modulating clot properties. In such a sce-
nario, it will be essential to elucidate what intrinsic charac-
teristics of diabetic C3 and fibrinogen underlie the observed
changes in clot lysis properties. Glycation of C3 may be a
plausible possibility [23]. It will also be interesting to see if
similar observations with respect to the role of C3 in hypo-
fibrinolysis can be made in type 2 diabetic individuals.
In summary, this commentary gives a brief overview of the
emerging roles of C3, C3a and C3a-desarg/ASP in adipose
tissue homeostasis, insulin resistance and (development of)
diabetes and related cardiometabolic diseases. The epidemio-
logical and experimental evidence presented supports a role
for these complement factors in metabolic, atherosclerotic/
atherothrombotic and microangiopathic processes. It should
be noted that an increasing number of additional complement
factors are reported to be expressed in adipose tissue in asso-
ciation with insulin resistance (for example, see [24]). Like-
wise, a range of additional complement components and
regulators have also been shown to be involved in the process
of atherosclerosis and atherothrombosis [25]. The current
s t u d yb yH e s se ta l[ 20] expands our knowledge of the
multifaceted role of the complement system, C3 in particular,
in the pathogenesis of diabetes-associated CVD. Further epi-
demiological, experimental and clinical studies are needed to
differentiate between, and determine the relevance of, differ-
ent aspects of complement function and activation in the
complex and inter-related processes that are characteristic of
cardiometabolic disorders.
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